Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21185893 | 0.98 | ESR1 (0.39) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL24475344 | 0.96 | CNR2 (0.40) | CNR2CNR1NAAACYP3A4CYP2D6 | |
| SCHEMBL19223950 | 0.96 | CNR2 (0.40) | CNR2CNR1NAAACYP3A4CYP2D6 | |
| SCHEMBL24871939 | 0.96 | CNR2 (0.40) | CNR2CNR1NAAACYP3A4CYP2D6 | |
| SCHEMBL21470858 | 0.95 | CNR2 (0.40) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL18852691 | 0.95 | CNR2 (0.40) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL19059382 | 0.94 | CYP3A4 (0.39) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL18612742 | 0.93 | ESR1 (0.40) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL19274594 | 0.93 | CYP3A4 (0.38) | CNR2CNR1NAAAESR1ESR2 | |
| SCHEMBL18910967 | 0.89 | CNR2 (0.39) | CNR2CNR1NAAAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20200031731-A1 | Gold-Catalyzed C-C Cross-Coupling of Boron- and Silicon-Containing Aryl Compounds and Aryldiazonium Compounds by Visible-Light | Universität Heidelberg (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | CNR2 2172/4885CNR1 2306/4885NAAA 123/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | CNR2 2172/4885CNR1 2306/4885NAAA 123/4885 |
| US-20200031731-A1 | Gold-Catalyzed C-C Cross-Coupling of Boron- and Silicon-Containing Aryl Compounds and Aryldiazonium Compounds by Visible-Light | HCCS, AHR, CTRC | CNR2 1373/4885CNR1 957/4885NAAA 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.